UGT1A1, GPX3, ADH1B, and ADH4 can serve as cross pathway regulatory nodes and can be integrated into a “metabolic immune prognostic model” in the future to optimize precision treatment strategies for gastric cancer. This evidence concerns the gene ADH1B and gastric cancer.